These findings underline the significance of cGAS/STING signaling as a potential therapeutic target in DCM, and the preclinical efficacy of STING inhibition as a new therapeutic strategy for the treatment of DCM. The gene discussed is CGAS; the disease is familial dilated cardiomyopathy.